Emergent Biosolutions EBS Allowance for Doubtful Accounts Receivable (Current)
Allowance for Doubtful Accounts Receivable (Current) at other companies
Other financials
Where this comes from
Reported directly by Emergent Biosolutions in its filing.
Tagged under the XBRL concept us-gaap:AllowanceForDoubtfulAccountsReceivable.
The official record: Emergent Biosolutions’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Emergent Biosolutions's allowance for doubtful accounts receivable (current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Emergent Biosolutions's allowance for doubtful accounts receivable (current)?
- Emergent Biosolutions (EBS) reported allowance for doubtful accounts receivable (current) of $800K in Q1 2026.
- How has Emergent Biosolutions's allowance for doubtful accounts receivable (current) changed year-over-year?
- Emergent Biosolutions's allowance for doubtful accounts receivable (current) decreased by 33.3% year-over-year, from $1.2M to $800K.
- What is the long-term trend for Emergent Biosolutions's allowance for doubtful accounts receivable (current)?
- Over 5 years (2020 to 2025), Emergent Biosolutions's allowance for doubtful accounts receivable (current) has grown at a -23.7% compound annual growth rate (CAGR), from $3.1M to $800K.
- What does allowance for doubtful accounts receivable (current) mean?
- This is the valuation allowance for current receivables that are considered uncollectible due to disputes, bankruptcy, or other non-payment issues. It serves as a buffer against potential losses from customer defaults. It is a critical indicator of the health of the company's accounts receivable portfolio.